Displaying 1521 - 1540 of 4915
Tronox/Cristal USA, In the Matter of
The FTC issued an administrative complaint (and authorized staff to seek a TRO and PI which have not been filed) challenging the merger of two top suppliers of chloride process titanium dioxide (TiO2), a white pigment used in a wide variety of products including paint, industrial coatings, plastic, and paper. The FTC’s administrative complaint charges that Tronox Limited’s proposed acquisition of competitor Cristal, for $1.67 billion and a 24 percent stake in the combined entity, would violate the antitrust laws by significantly reducing competition in the North American market (comprised of the United States and Canada) for chloride process titanium dioxide. The FTC alleges that the acquisition, if consummated, would increase the risk of coordinated action among the remaining competitors, and increase the risk of future anticompetitive output reductions by Tronox.
1905001 Informal Interpretation
FTC Staff Issues FY 2016 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
Statement of Commissioner Rohit Chopra on the Ruling by Judge Lucy Koh in Federal Trade Commission v. Qualcomm Incorporated
Statement by Federal Trade Commission Bureau of Competition Director Bruce Hoffman on District Court Ruling in Agency’s Monopolization Case against Qualcomm
International Competition Network Adopts Framework for Competition Agency Procedures and Recommended Practices on Investigative Process and Announces the U.S. Agencies will Host the 2020 ICN Annual Conference
1905002 Informal Interpretation
1905005 Informal Interpretation
FTC Chairman Joseph J. Simons to Participate in International Competition Network Conference in Cartagena, Colombia
FTC Announces 14th and Final Session of its Hearings on Competition and Consumer Protection in the 21st Century
FTC Hearing #14: Roundtable with State Attorneys General
FTC Staff Comment to the FDA Department of Health and Human Services on Its Updated Guidance for Industry on the “Nonproprietary Naming of Biological Products”
FTC Submits Comment on FDA Guidance Regarding Nonproprietary Naming of Biological Products
Prepared Statement of the Federal Trade Commission: “Oversight of the Federal Trade Commission,” Before the Subcommittee on Consumer Protection and Commerce, United States House of Representatives Committee on Energy and Commerce
Displaying 1521 - 1540 of 4915